Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
Completed · Not applicable · NCT06351358
Conditions: Photoaging, Weight Loss, Skin Laxity, Photodamaged Skin, Volume Deficiency of the Midface
At a glance
- Research payments reported, 2025
- $231,035
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 41
About the trial
- Sponsor
- Galderma R&D
- Tested
- Sculptra treatment (device), Restylane Treatment (device)
- Dates
- Started 2024-02-19; completion 2025-05-31
- Results posted
- Not yet
Adult subjects with a history of or currently taking glucagon-like peptide-1 (GLP-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with Sculptra correction of fine lines and wrinkles in the cheek area and Restylane Lyft or Restylane Contour for cheek augmentation and correction of midface contour deficiencies.
From ClinicalTrials.gov, last updated 2026-04-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Galderma Laboratories, L.P. reported $231,035 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael T. Somenek, M.D. Facial Plastic Surgery · Washington, DC
- Zbigniew P. Lorenc, M.D., F.A.C.S. Plastic Surgery · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lorenc Aesthetic Plastic Surgery Center $172,500
- Advanced Plastic Surgery $58,535
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.